June 20, 2022 Columns by Ed Tobias MS News That Caught My Eye Last Week: Vidofludimus Calcium, Foralumab, Exoskeleton, Dysport Vidofludimus Calcium Safely Reduced RRMS Brain Lesions Vidofludimus calcium, also called IMU-838, is an oral therapy designed to reduce the activity of B- and T-cells. These are immune cells believed to be responsible for the inflammation that results in MS damage. In this small study, active lesions ā including…
June 14, 2022 News by Margarida Maia, PhD Dysport Wins Positive Opinion in Europe for Treating Bladder Issues Dysport (abobotulinumtoxinA), a form of purified botulinum toxin, has received a positive opinion in Europe for managing urinary incontinence in adults with neurogenic detrusor overactivity (NDO), or overactive bladder. The opinion is specifically for those who experience bladder issues due to multiple sclerosis (MS) or spinal cord…
June 10, 2022 Columns by John Connor My Right Arm Is Going to Look Really Young I’ve just received four intramuscular Botox injections in my right arm to relieve the muscle spasticity that comes with multiple sclerosis. (OK, it wasnāt actually Botox, but Dysport, or abobotulinumtoxinA, another medication derived from the botulinum toxin to block muscle contractions.) And “my right arm is going…
June 26, 2017 Columns by Ed Tobias MS News That Caught My Eye This Week: Brain Scans, Spasticity, Tecfidera Study and Cigarettes In case you missedĀ them, here are some news stories that appeared in MS News Today that caught my eye over the past week. **** Harvard Study Finds No Link Between Clinical Exams and MRIs in Some MS Patients I’m really not surprised…
June 19, 2017 News by Alice MelĆ£o, MSc FDA Expands Dysportās Approval for Treatment of Lower Limb Spasticity in Adults The U.S. Food and Drug Administration (FDA) has expanded approval of Dysport (abobotulinumtoxinA) for treatment of spasticity in adults, a condition that affects many people in the United States, including multiple sclerosis patients. The decision was based on Dysportās supplemental Biologics License Application (sBLA)…
December 8, 2014 News by Isaura Santos Ipsen Biopharmaceuticals Announces FDA To Review sBLA For DysportĀ® As Treatment For Upper Limb Spasticity Ipsen Biopharmaceuticals, IncĀ announced that the United States Food and Drug Administration (FDA) has agreed to review theĀ supplemental Biologics License Application (sBLA) for DysportĀ®Ā (abobotulinumtoxinA)Ā to treat upper limbĀ spasticity, a condition that affects many people in the United States, including multiple sclerosis (MS)…